Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Properties of Organometallic Compounds01:23

Properties of Organometallic Compounds

Organometallic compounds are compounds that contain a carbon–metal bond. Carbon belongs to an organyl group like alkyl, aryl, allyl, or benzyl groups. The metal can be from Group I or Group II of the periodic table, a transition metal, or a semimetal.
Properties of Transition Metals02:58

Properties of Transition Metals

Transition metals are defined as those elements that have partially filled d orbitals. As shown in Figure 1, the d-block elements in groups 3–12 are transition elements. The f-block elements, also called inner transition metals (the lanthanides and actinides), also meet this criterion because the d orbital is partially occupied before the f orbitals.
Metal-Ligand Bonds02:51

Metal-Ligand Bonds

The hemoglobin in the blood, the chlorophyll in green plants, vitamin B-12, and the catalyst used in the manufacture of polyethylene all contain coordination compounds. Ions of the metals, especially the transition metals, are likely to form complexes.
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PregMedNet: Multifaceted maternal medication impacts on neonatal complications.

Nature communications·2026
Same author

Red Blood Cell Transfusions: Evidence Favors a Restrictive Approach in Neonates.

Anesthesia and analgesia·2026
Same author

Triglyceride profiles in preterm infants reveal dynamic and age-specific trajectories.

Frontiers in pediatrics·2026
Same author

Plasma or Serum? A Pilot Evaluation of Matrix Selection for Integrated Metabolomics and Exposomics of Clinical Samples.

Toxics·2026
Same author

AI Guided Parenteral Nutrition Therapy After Hematopoietic Stem Cell Transplantation.

NPJ digital medicine·2026
Same author

Single-cell spatiotemporal dissection of the human maternal-fetal interface.

Nature·2026

Related Experiment Video

Updated: May 22, 2026

Porphyrin-Modified Beads for Use as Compensation Controls in Flow Cytometry
10:06

Porphyrin-Modified Beads for Use as Compensation Controls in Flow Cytometry

Published on: March 24, 2023

Metalloporphyrins - an update.

Stephanie Schulz1, Ronald J Wong, Hendrik J Vreman

  • 1Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine Stanford, CA, USA.

Frontiers in Pharmacology
|May 5, 2012
PubMed
Summary

Metalloporphyrins offer a promising therapeutic strategy for neonatal hyperbilirubinemia by inhibiting heme oxygenase, an enzyme crucial for bilirubin production. Research focuses on developing safe and effective metalloporphyrins for clinical use.

Keywords:
bilirubinheme oxygenasehemolysisneonatal hyperbilirubinemia

More Related Videos

A Technical Guide for Performing Spectroscopic Measurements on Metal-Organic Frameworks
10:13

A Technical Guide for Performing Spectroscopic Measurements on Metal-Organic Frameworks

Published on: April 28, 2023

Cercosporin-Photocatalyzed [4+1]- and [4+2]-Annulations of Azoalkenes Under Mild Conditions
07:12

Cercosporin-Photocatalyzed [4+1]- and [4+2]-Annulations of Azoalkenes Under Mild Conditions

Published on: July 17, 2020

Related Experiment Videos

Last Updated: May 22, 2026

Porphyrin-Modified Beads for Use as Compensation Controls in Flow Cytometry
10:06

Porphyrin-Modified Beads for Use as Compensation Controls in Flow Cytometry

Published on: March 24, 2023

A Technical Guide for Performing Spectroscopic Measurements on Metal-Organic Frameworks
10:13

A Technical Guide for Performing Spectroscopic Measurements on Metal-Organic Frameworks

Published on: April 28, 2023

Cercosporin-Photocatalyzed [4+1]- and [4+2]-Annulations of Azoalkenes Under Mild Conditions
07:12

Cercosporin-Photocatalyzed [4+1]- and [4+2]-Annulations of Azoalkenes Under Mild Conditions

Published on: July 17, 2020

Area of Science:

  • Pharmacology and Toxicology
  • Neonatal Medicine
  • Biochemistry

Background:

  • Neonatal hyperbilirubinemia is a common condition requiring effective management strategies.
  • Metalloporphyrins, structural analogs of heme, have been investigated for over 30 years for this purpose.
  • The underlying mechanism involves the inhibition of heme oxygenase (HO), the rate-limiting enzyme in bilirubin synthesis.

Purpose of the Study:

  • To explore the therapeutic potential of metalloporphyrins in managing neonatal hyperbilirubinemia.
  • To understand the pharmacological basis of metalloporphyrin action on bilirubin production.
  • To guide ongoing research towards identifying ideal metalloporphyrin candidates.

Main Methods:

  • Review of existing research on metalloporphyrins and heme oxygenase inhibition.
  • Pharmacological analysis of metalloporphyrin efficacy and safety profiles.
  • Investigation into defining therapeutic windows and targeted interventions.

Main Results:

  • Metalloporphyrins effectively block bilirubin production by inhibiting heme oxygenase.
  • Decades of research have established the pharmacological basis for their use.
  • Ongoing studies aim to optimize metalloporphyrin characteristics for clinical application.

Conclusions:

  • Metalloporphyrins represent a viable therapeutic class for controlling excessive bilirubin levels in neonates.
  • Further research is essential to identify safe and effective metalloporphyrins with defined therapeutic parameters.
  • Targeted interventions using optimized metalloporphyrins hold promise for treating neonatal hyperbilirubinemia.